List of Excipients in Branded Drug XATMEP

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	XATMEP	methotrexate	52652-2001	CITRIC ACID MONOHYDRATE
Azurity Pharmaceuticals Inc	XATMEP	methotrexate	52652-2001	HYDROCHLORIC ACID
Azurity Pharmaceuticals Inc	XATMEP	methotrexate	52652-2001	METHYLPARABEN SODIUM
Azurity Pharmaceuticals Inc	XATMEP	methotrexate	52652-2001	PROPYLPARABEN SODIUM

XATMEP Excipient Strategy and Commercial Opportunities in Pediatric Methotrexate

Last updated: August 17, 2026

XATMEP is a ready-to-use methotrexate oral solution containing 2.5 mg/mL methotrexate. Its commercial value comes from converting a high-risk, historically compounded medicine into a standardized pediatric dosage form. The strongest excipient opportunities are dose-measurement accuracy, palatability, preservative systems, stability, caregiver usability, and differentiated presentations for hospitals, specialty pharmacies, and home administration.

What is XATMEP and why does its excipient system matter?

XATMEP is an oral solution of methotrexate indicated for pediatric patients with acute lymphoblastic leukemia as part of a maintenance regimen and for pediatric patients with polyarticular juvenile idiopathic arthritis. The product is marketed by Azurity Pharmaceuticals.[1]

The labeled strength is 2.5 mg/mL. Because methotrexate has a narrow therapeutic margin and dosing errors can cause severe or fatal toxicity, the formulation must support accurate weekly dosing and minimize confusion with daily medicines.[1,2]

The commercial formulation uses a liquid vehicle with buffering, sweetening, flavoring, and preservative functions. The inactive ingredients listed in the prescribing information include:

Excipient or component	Primary formulation role	Commercial relevance
Purified water	Aqueous vehicle	Supports an immediately usable liquid dosage form
Sodium citrate dihydrate	Buffering and pH control	Helps maintain chemical stability and taste profile
Citric acid anhydrous	Acidulant and buffer component	Controls pH and contributes to flavor balance
Glycerin	Co-solvent, humectant, mouthfeel modifier	Improves viscosity and oral sensation
Sucralose	High-intensity sweetener	Reduces bitterness without adding substantial sugar load
Methylparaben	Antimicrobial preservative	Supports multidose container stability
Propylparaben	Antimicrobial preservative	Complements methylparaben across preservative activity
Cherry flavor	Taste masking	Improves pediatric acceptability

The formulation strategy is conventional but commercially effective. It combines a low-viscosity aqueous product with sweetness, fruit flavor, buffering, and a dual-paraben preservative system. That design reduces the need for caregivers or pharmacies to compound methotrexate suspensions or solutions.

What excipient problems must a competing XATMEP formulation solve?

A competing formulation must address five technical constraints: methotrexate stability, dose accuracy, taste, microbial control, and packaging compatibility.

Methotrexate stability

Methotrexate is sensitive to formulation conditions, including pH, light, temperature, and aqueous storage. A commercial oral solution requires validated potency, impurity control, preservative effectiveness, and in-use stability over the labeled shelf life.

The central development question is not whether methotrexate can be dissolved in water. It is whether the formulation can maintain assay and impurity specifications throughout storage and repeated container opening.

Potential formulation approaches include:

• Citrate or phosphate buffering at a controlled pH.
• Alternative buffering systems that reduce taste impact.
• Chelation or oxygen-control strategies if degradation pathways justify them.
• Light-protective packaging.
• Unit-dose packaging that reduces repeated exposure to air and contamination.

Any change in buffer, preservative, flavor, or sweetener requires compatibility and stability testing. Excipients that improve taste can affect pH, viscosity, osmolality, microbial growth, or methotrexate degradation.

Dose accuracy

At 2.5 mg/mL, a 10 mg dose equals 4 mL. A 20 mg dose equals 8 mL. Large pediatric doses can therefore require substantial liquid volumes.

Commercial opportunity exists in improving dose delivery through:

• Oral syringes with low dead space.
• Dose markings aligned to common methotrexate doses.
• Adapters that reduce spills and leakage.
• Unit-dose cups or prefilled oral syringes.
• Packaging that prevents use of household teaspoons.
• Integrated instructions that reinforce once-weekly administration.

The device and package can be as commercially important as the excipient system. FDA labeling specifically warns against daily administration and recommends clear dosing communication because accidental daily use can result in fatal toxicity.[1]

Taste masking

Methotrexate can present bitterness or medicinal notes. XATMEP uses cherry flavor and sucralose to improve acceptability. A competing product could differentiate through:

• Alternative fruit profiles, such as grape, berry, or orange.
• Dual-flavor systems that suppress aftertaste.
• Taste-masking polymers or ion-exchange resins.
• Lower-intensity sweetener systems for patients sensitive to intense sweetness.
• Sugar-free and reduced-osmolality versions.
• Flavor options for children who reject cherry taste.

Taste masking must be evaluated in the target pediatric population. Adult sensory panels may not predict acceptance among young children with chronic dosing requirements.

Preservative systems

XATMEP uses methylparaben and propylparaben. The combination is established in oral liquid products, but competing developers may pursue alternative preservative systems to respond to parent preferences, preservative sensitivity, or market access requirements.

Potential alternatives include:

• Potassium sorbate or sorbic acid.
• Sodium benzoate or benzoic acid.
• Benzyl alcohol, subject to pediatric suitability limitations.
• Preservative-free unit-dose packaging.
• Aseptic or sterile single-use presentations.

A preservative-free product could command a premium in hospitals and specialty pharmacies if it demonstrates meaningful benefits in contamination control, tolerability, or administration. The tradeoff is higher packaging cost and potentially lower convenience for chronic home use.

What XATMEP formulation patents or regulatory protections matter?

The primary commercial protection for XATMEP is likely to arise from a combination of FDA approval, product-specific patents if listed, formulation know-how, trademarks, manufacturing controls, and distribution relationships.

Orange Book status

XATMEP is an FDA-approved prescription drug. The FDA Orange Book should be checked for current patent and exclusivity listings associated with the product’s NDA before making a launch or freedom-to-operate decision.[3]

The key diligence items are:

Diligence item	Commercial significance
NDA number and listed product	Establishes the approved reference product
Patent numbers	Defines potential listed patent barriers
Patent expiration dates	Establishes timing risk for an ANDA applicant
Pediatric exclusivity	Can extend listed patent protection by six months
Regulatory exclusivity	May restrict reliance on the reference product for a defined period
Approved dosage form and strength	Determines whether an ANDA or 505(b)(2) pathway is available
Method-of-use listings	May affect labeling and carve-out strategy

The approved product is an oral solution rather than a tablet, injectable product, or extemporaneous compounded preparation. A generic applicant seeking approval of the same dosage form would need to address pharmaceutical equivalence, bioequivalence requirements, labeling, manufacturing, and any listed patents.

Formulation and method-of-use protection

The most commercially relevant claim categories for a product such as XATMEP are likely to include:

• Methotrexate oral solutions at a defined concentration.
• Specific pH ranges.
• Buffer systems.
• Preservative combinations.
• Flavor and sweetener combinations.
• Stability profiles.
• Container-closure systems.
• Dosing methods for pediatric oncology or juvenile idiopathic arthritis.

A broad composition claim may be difficult to enforce if alternative buffers, preservatives, or flavor systems can produce equivalent performance. Narrower claims covering a particular stability profile, preservative combination, or packaging configuration may be more defensible if supported by comparative data.

Manufacturing and know-how barriers

The main manufacturing barriers are not raw-material scarcity. Methotrexate is an established active pharmaceutical ingredient with multiple suppliers. The barriers are process control and quality assurance.

Important control points include:

• Uniform drug concentration throughout filling.
• Prevention of cross-contamination with cytotoxic materials.
• Control of methotrexate degradation products.
• Accurate low-dose filling and container closure.
• Preservative assay and antimicrobial effectiveness.
• Cleaning validation.
• Stability-indicating analytical methods.
• Segregated handling in the manufacturing facility.

These controls create a practical barrier even when patent protection is limited. A new entrant would need validated production capacity and a compliant supply chain for pediatric liquid packaging.

When does XATMEP lose exclusivity and face generic competition?

The timing of generic risk depends on FDA-listed patents, regulatory exclusivity, pediatric exclusivity, and the commercial attractiveness of the market. Product-level expiration dates must be verified against current FDA Orange Book records and relevant patent databases.[3,4]

A generic competitor could pursue an ANDA for methotrexate oral solution if it can demonstrate pharmaceutical equivalence and bioequivalence. A 505(b)(2) application could be relevant for a materially different formulation, such as:

• A different concentration.
• A preservative-free product.
• A different flavor or sweetener system.
• A unit-dose presentation.
• A modified-release or otherwise clinically differentiated formulation.

The generic launch scenarios are:

1. A same-strength oral solution with a conventional excipient system.
2. A lower-cost pharmacy or institutional product.
3. A preservative-free unit-dose product.
4. A more palatable pediatric formulation.
5. A product packaged with a differentiated oral syringe or dose-management system.

The greatest risk to XATMEP is likely to come from a product that matches its concentration and indication while reducing acquisition cost. A differentiated product may compete more on adherence and safety than on price.

What commercial opportunities exist for XATMEP excipients?

Premium pediatric presentations

The most direct opportunity is a premium pediatric line built around administration needs. Potential presentations include:

• 2.5 mg/mL standard oral solution.
• Higher-concentration solution for patients requiring large doses.
• Preservative-free single-use sachets or syringes.
• Multiple flavor options.
• Ready-to-administer hospital doses.
• Starter kits containing an oral syringe, adapter, and dosing guide.

A higher concentration could reduce administration volume, but it would increase the risk of tenfold dosing errors if patients or caregivers confuse concentrations. Any concentration change would require prominent labeling, device redesign, and a separate risk assessment.

Specialty pharmacy and home-delivery packaging

Methotrexate therapy often involves specialty care, repeated refills, and caregiver administration. Packaging designed for shipment and home storage can create value through:

• Tamper-evident closures.
• Child-resistant packaging.
• Temperature and light protection.
• Leak-resistant secondary packaging.
• Unit-dose labeling.
• Refill synchronization.
• Barcoded dose documentation.

These features may support contracts with specialty pharmacies, pediatric hospitals, and integrated delivery networks.

Hospital and institutional formulations

Hospitals may value unit-dose products that reduce pharmacy preparation and cytotoxic compounding. Opportunities include:

• Pharmacy-ready bottles with calibrated administration devices.
• Unit-dose oral syringes.
• Barcoded packaging for medication administration systems.
• Preservative-free doses for defined inpatient use.
• Formulations optimized for nasogastric or enteral administration, subject to compatibility validation.

An enteral-administration claim would require data on tube compatibility, adsorption, recovery, clogging, and dose delivery.

Excipient supplier opportunities

Excipient suppliers can compete by offering:

• Pediatric-grade flavor systems.
• Low-peroxide or low-reactive excipients.
• Preservative systems compatible with methotrexate.
• Taste-masking technologies.
• Ready-to-use liquid premixes.
• Documentation packages supporting FDA excipient review.
• Container-closure systems with validated methotrexate compatibility.

The strongest supplier opportunity is an integrated formulation package rather than a single commodity ingredient. A supplier that can provide flavor, sweetener, buffer, preservative, stability data, and regulatory documentation can reduce development time for generic and 505(b)(2) applicants.

How does XATMEP compare with compounded methotrexate liquids?

Attribute	XATMEP	Pharmacy-compounded liquid
Concentration	Standardized at 2.5 mg/mL	May vary by pharmacy
Manufacturing	Commercial GMP production	Pharmacy-specific preparation
Taste	Standardized cherry-flavored formulation	Variable
Stability	Product-specific labeled shelf life	Depends on formulation and beyond-use dating
Dose device	Commercially specified	May vary
Supply	Prescription distribution	Dependent on compounding capacity
Quality controls	Centralized release testing	Pharmacy-level controls
Cost	May be higher acquisition cost	Potentially lower or variable
Error risk	Standardized concentration	Higher if concentrations differ

XATMEP’s commercial proposition is strongest where standardized concentration, supply reliability, and caregiver usability are valued. Compounding remains a competitive alternative where reimbursement is limited or local pharmacy access is strong.

What FDA regulatory issues affect new XATMEP-like products?

A new product must select its regulatory pathway based on the degree of similarity to XATMEP.

ANDA pathway

An ANDA is most suitable for a product that matches the reference product in active ingredient, dosage form, strength, route, and other pharmaceutical-equivalence requirements. Excipient differences may be acceptable if they do not affect safety, performance, or bioequivalence.

505(b)(2) pathway

A 505(b)(2) application may support a formulation with clinically meaningful differences, such as a new concentration, new dosing device, preservative-free presentation, or alternative administration route. The applicant may need additional clinical, pharmacokinetic, local tolerability, or safety information.

Pediatric formulation requirements

FDA pediatric formulation guidance emphasizes palatability, dose-volume reduction, age-appropriate devices, excipient safety, and caregiver usability.[5] Excipients require special review in neonates, infants, and young children. Benzyl alcohol, ethanol, propylene glycol, high osmolarity, and certain sweeteners can create age-specific concerns.

XATMEP’s indicated populations include children and adolescents, making pediatric excipient tolerability and administration data central to market differentiation.

How strong is the XATMEP patent estate?

Patent strength depends on the scope and remaining life of any listed patents, not on the product’s commercial branding. The strongest potential protection would cover a narrow combination of concentration, buffer, preservative, flavor, stability, and packaging features that competitors cannot easily design around.

A weaker estate would rely primarily on broad claims to methotrexate oral solutions because alternative excipient systems may be available. In that case, formulation know-how, manufacturing validation, distribution access, and prescriber familiarity become more important than patent exclusion.

The commercial risk profile is therefore mixed:

Risk factor	Assessment
API availability	Low barrier
Basic oral-solution technology	Moderate to low barrier
Pediatric taste masking	Moderate barrier
Stability and preservative validation	Moderate barrier
Cytotoxic manufacturing controls	Moderate to high practical barrier
Dose-device integration	Moderate barrier
Patent protection	Requires current Orange Book and patent review
Reimbursement pressure	Material risk
Compounding substitution	Material risk in price-sensitive channels

Key Takeaways

• XATMEP is a 2.5 mg/mL methotrexate oral solution designed for pediatric oncology and polyarticular juvenile idiopathic arthritis.
• Its excipient strategy combines citrate buffering, glycerin, sucralose, cherry flavor, and methylparaben-propylparaben preservation.
• The largest commercial opportunities are improved dose accuracy, better taste, preservative-free unit doses, lower administration volume, and specialty-pharmacy packaging.
• A same-strength ANDA product would pose the clearest price-based threat.
• A 505(b)(2) product could compete through concentration, flavor, packaging, enteral compatibility, or preservative-free design.
• Methotrexate manufacturing requires strong contamination controls, validated stability methods, and precise liquid filling.
• Product-specific patent and exclusivity dates must be confirmed through current FDA Orange Book records and patent filings.
• No public product-level revenue figure for XATMEP establishes its commercial exposure; market opportunity is better assessed through prescription volume, payer coverage, hospital adoption, and competing compounded products.

FAQs

Can XATMEP be reformulated with a different flavor?

Yes. A different flavor would generally require formulation, stability, preservative-effectiveness, palatability, and regulatory assessment. The flavor must not alter methotrexate assay, impurities, pH, viscosity, or microbial performance.

Is a preservative-free methotrexate oral solution commercially viable?

Yes, particularly in unit-dose hospital or specialty-pharmacy formats. The product would need packaging that limits microbial contamination and validated in-use or single-use stability data.

Could a higher-strength methotrexate solution compete with XATMEP?

Yes, but concentration changes create medication-error risk. A higher-strength product would need distinct labeling, dedicated devices, concentration-specific education, and a regulatory strategy addressing the difference from the reference product.

Which excipients are most likely to differentiate a generic methotrexate liquid?

Taste-masking agents, alternative sweeteners, preservative systems, viscosity modifiers, and packaging-compatible buffers offer the most practical differentiation. Commodity vehicle changes alone are unlikely to create durable commercial separation.

Can a methotrexate oral solution be marketed for enteral-tube administration?

Potentially, but the applicant would need data on tube compatibility, drug recovery, adsorption, clogging, flushing requirements, and dose accuracy. An enteral-use claim could support a differentiated 505(b)(2) strategy.

References

1. Azurity Pharmaceuticals, Inc. (2024). XATMEP (methotrexate) oral solution: Prescribing information. U.S. Food and Drug Administration.

2. Institute for Safe Medication Practices. (2022). Methotrexate safety recommendations for oral dosing. Institute for Safe Medication Practices.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (2025). Patent Center. U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (2021). Quality considerations for chewable tablets and other orally administered pediatric dosage forms. FDA.